Novo Nordisk A/S (NYSE:NVO) Shares Sold by Gallacher Capital Management LLC

Gallacher Capital Management LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,074 shares of the company’s stock after selling 242 shares during the quarter. Gallacher Capital Management LLC’s holdings in Novo Nordisk A/S were worth $628,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. CNB Bank acquired a new stake in Novo Nordisk A/S in the fourth quarter worth $26,000. Pacific Center for Financial Services boosted its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. Valued Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth about $28,000. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. Finally, Tyler Stone Wealth Management grew its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after buying an additional 146 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.8 %

Shares of Novo Nordisk A/S stock traded down $0.97 on Friday, reaching $123.05. 5,932,926 shares of the company were exchanged, compared to its average volume of 3,905,318. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The stock has a fifty day moving average price of $127.20 and a 200-day moving average price of $113.10.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current year.

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.